{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T12:18:26Z","timestamp":1791029906284,"version":"4.1.0"},"reference-count":29,"publisher":"The Endocrine Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A high prevalence of activating mutation of the B type Raf kinase (BRAF) gene was recently reported in papillary thyroid cancer (PTC). However, the frequency of this mutation in several other types of thyroid neoplasms was not thoroughly investigated. In the present study, in addition to PTC, we evaluated various thyroid tumor types for the most common BRAF T1796A mutation by direct genomic DNA sequencing. We found a high and similar frequency (45%) of the BRAF T1796A mutation in two geographically distinct PTC patient populations: one composed of sporadic cases from North America, and the other from Kiev, Ukraine, that included individuals who were exposed to the Chernobyl nuclear accident. In contrast, we found BRAF mutation in only 20% of anaplastic thyroid cancers and no mutation in medullary thyroid cancers and benign thyroid hyperplasia. We also confirmed previous reports that the BRAF T1796A mutation did not occur in benign thyroid adenomas and follicular thyroid cancers. Specific analysis of the Ukraine patients with confirmed history of radiation exposure failed to show a higher incidence of BRAF mutation. Our results suggest that frequent occurrence of BRAF mutation is inherently associated with PTC, irrespective of geographic origin, and is apparently not a radiation-susceptible mutation. The lack or low prevalence of BRAF mutation in other thyroid neoplasms is consistent with the notion that other previously defined genetic alterations on the same signaling pathway are sufficient to cause tumorigenesis in most thyroid neoplasms.<\/jats:p>","DOI":"10.1210\/jc.2003-031488","type":"journal-article","created":{"date-parts":[[2004,3,5]],"date-time":"2004-03-05T01:53:04Z","timestamp":1078451584000},"page":"1365-1368","source":"Crossref","is-referenced-by-count":93,"title":["BRAF T1796A Transversion Mutation in Various Thyroid Neoplasms"],"prefix":"10.1210","volume":"89","author":[{"given":"M.","family":"Xing","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Metabolism, Departments of Medicine (M.X., P.W.L.), Baltimore, Maryland 21205"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Vasko","sequence":"additional","affiliation":[{"name":"Washington Hospital Center and Medstar Research Institute (V.V., M.D.R.), Washington, DC 20010"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Tallini","sequence":"additional","affiliation":[{"name":"Departments of Pathology (G.T.), New Haven, Connecticut 06520"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Larin","sequence":"additional","affiliation":[{"name":"Hospital for Endocrine Surgery (A.L.), Kiev, 252000 Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gujun","family":"Wu","sequence":"additional","affiliation":[{"name":"Otolaryngology-Head and Neck Surgery (G.W., D.S.), the Johns Hopkins University School of Medicine, Baltimore, Maryland 21205"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Udelsman","sequence":"additional","affiliation":[{"name":"Surgery (R.U.), Yale University School of Medicine, New Haven, Connecticut 06520"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. D.","family":"Ringel","sequence":"additional","affiliation":[{"name":"Washington Hospital Center and Medstar Research Institute (V.V., M.D.R.), Washington, DC 20010"},{"name":"Division of Endocrinology and Metabolism, The Ohio State University (M.D.R.), Columbus, Ohio 43235"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. W.","family":"Ladenson","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Departments of Medicine (M.X., P.W.L.), Baltimore, Maryland 21205"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Sidransky","sequence":"additional","affiliation":[{"name":"Otolaryngology-Head and Neck Surgery (G.W., D.S.), the Johns Hopkins University School of Medicine, Baltimore, Maryland 21205"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071617474726200_R1","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1002\/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1","article-title":"A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U. S., 1985\u20131995.","volume":"83","author":"Hundahl","year":"1998","journal-title":"Cancer"},{"key":"2020071617474726200_R2","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1172\/JCI115743","article-title":"Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype.","volume":"89","author":"Santoro","year":"1992","journal-title":"J Clin Invest"},{"key":"2020071617474726200_R3","first-page":"1331","article-title":"Detection of the PTC\/retTPC oncogene in human thyroid cancers.","volume":"7","author":"Jhiang","year":"1992","journal-title":"Oncogene"},{"key":"2020071617474726200_R4","first-page":"5617","article-title":"Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident.","volume":"55","author":"Fugazzola","year":"1995","journal-title":"Cancer Res"},{"key":"2020071617474726200_R5","first-page":"1690","article-title":"Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children.","volume":"57","author":"Nikiforov","year":"1997","journal-title":"Cancer Res"},{"key":"2020071617474726200_R6","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/sj.onc.1200206","article-title":"High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation.","volume":"15","author":"Bounacer","year":"1997","journal-title":"Oncogene"},{"key":"2020071617474726200_R7","first-page":"4459","article-title":"Activated ras oncogenes in human thyroid cancers.","volume":"48","author":"Lemoine","year":"1988","journal-title":"Cancer Res"},{"key":"2020071617474726200_R8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1098-2264(199605)16:1<1::AID-GCC1>3.0.CO;2-4","article-title":"Cytogenetics and molecular genetics of carcinomas arising from thyroid epithelial follicular cells.","volume":"16","author":"Pierotti","year":"1996","journal-title":"Genes Chromosomes Cancer"},{"key":"2020071617474726200_R9","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1210\/jc.2002-021186","article-title":"Specific pattern of RAS oncogene mutations in follicular thyroid tumors.","volume":"88","author":"Vasko","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071617474726200_R10","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1210\/jc.2002-021907","article-title":"RAS point mutations and PAX8-PPAR \u03b3 rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.","volume":"88","author":"Nikiforova","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071617474726200_R11","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1126\/science.289.5483.1357","article-title":"PAX8-PPAR\u03b31 fusion oncogene in human thyroid carcinoma.","volume":"289","author":"Kroll","year":"2000","journal-title":"Science"},{"key":"2020071617474726200_R12","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1172\/JCI116168","article-title":"High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.","volume":"91","author":"Fagin","year":"1993","journal-title":"J Clin Invest"},{"key":"2020071617474726200_R13","first-page":"151","article-title":"Molecular biology of thyroid neoplasms.","volume":"25","author":"Satta","year":"2000","journal-title":"Rays"},{"key":"2020071617474726200_R14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0030-6665(02)00136-6","article-title":"Medullary thyroid cancer.","volume":"36","author":"Clayman","year":"2003","journal-title":"Otolaryngol Clin North Am"},{"key":"2020071617474726200_R15","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1056\/NEJMoa020152","article-title":"Germ-line mutations in nonsyndromic pheochromocytoma.","volume":"346","author":"Neumann","year":"2002","journal-title":"N Engl J Med"},{"key":"2020071617474726200_R16","first-page":"1454","article-title":"High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET\/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.","volume":"63","author":"Kimura","year":"2003","journal-title":"Cancer Res"},{"key":"2020071617474726200_R17","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/jnci\/95.8.625","article-title":"BRAF mutation in papillary thyroid carcinoma.","volume":"95","author":"Cohen","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"2020071617474726200_R18","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1038\/sj.onc.1206706","article-title":"BRAF mutations and RET\/PTC rearrangements are alternative events in the etiopathogenesis of PTC.","volume":"22","author":"Soares","year":"2003","journal-title":"Oncogene"},{"key":"2020071617474726200_R19","first-page":"4561","article-title":"High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.","volume":"63","author":"Xu","year":"2003","journal-title":"Cancer Res"},{"key":"2020071617474726200_R20","first-page":"511","article-title":"The Ras-Raf-MEK-ERK pathway in the treatment of cancer.","volume":"25","author":"Hilger","year":"2002","journal-title":"Onkologie"},{"key":"2020071617474726200_R21","first-page":"25","article-title":"Raf proteins and cancer: B-Raf is identified as a mutational target.","volume":"1653","author":"Mercer","year":"2003","journal-title":"Biochim Biophys Acta"},{"key":"2020071617474726200_R22","first-page":"795","article-title":"B-raf and a B-raf pseudogene are located on 7q in man.","volume":"7","author":"Sithanandam","year":"1992","journal-title":"Oncogene"},{"key":"2020071617474726200_R23","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer.","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"2020071617474726200_R24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/ng1054","article-title":"High frequency of BRAF mutations in nevi.","volume":"33","author":"Pollock","year":"2003","journal-title":"Nat Genet"},{"key":"2020071617474726200_R25","first-page":"2316","article-title":"Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing.","volume":"63","author":"Xing","year":"2003","journal-title":"Cancer Res"},{"key":"2020071617474726200_R26","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1054\/bjoc.1999.0921","article-title":"Gene rearrangement and Chernobyl related thyroid cancers.","volume":"82","author":"Santoro","year":"2000","journal-title":"Br J Cancer"},{"key":"2020071617474726200_R27","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1053\/beem.2000.0103","article-title":"Thyroid nodules: pathogenesis, diagnosis and treatment.","volume":"14","author":"Meier","year":"2000","journal-title":"Baillieres Best Pract Res Clin Endocrinol Metab"},{"key":"2020071617474726200_R28","first-page":"2207","article-title":"Ret receptor tyrosine kinase activates extracellular signal-regulated kinase 2 in SK-N-MC cells.","volume":"11","author":"Weering","year":"1995","journal-title":"Oncogene"},{"key":"2020071617474726200_R29","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/sj.onc.1200911","article-title":"Cell scattering of SK-N-MC neuroepithelioma cells in response to Ret and FGF receptor tyrosine kinase activation is correlated with sustained ERK2 activation.","volume":"14","author":"Puijenbroek","year":"1997","journal-title":"Oncogene"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/89\/3\/1365\/10743712\/jcem1365.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/89\/3\/1365\/10743712\/jcem1365.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T03:38:34Z","timestamp":1594957114000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/89\/3\/1365\/2844480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3,1]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,3,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2003-031488","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,3,1]]}}}